Full data from the trial position the Pharmamar/Jazz small-cell lung cancer drug to remain safely on the US market.
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.
NOV03 posts a pivotal win but the late-stage dry eye pipeline is crowded.
A focus on rare diseases and regulatory acceptance of cannabis make GW the subject of a $7.2bn buyout.
Pharmamar’s pivotal small cell lung cancer trial is finally confirmed a dud, but will the FDA pull Zepzelca from the market?
Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.